Published in J Crohns Colitis on April 26, 2009
Long-term outcomes of cytomegalovirus reactivation in patients with moderate to severe ulcerative colitis: a multicenter study. Gut Liver (2014) 1.38
Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf (2013) 1.31
Clinical significance of cytomegalovirus infection in patients with inflammatory bowel disease. World J Gastroenterol (2013) 1.28
Cytomegalovirus positive ulcerative colitis: A single center experience and literature review. World J Gastrointest Pathophysiol (2013) 1.21
Defining quality indicators for best-practice management of inflammatory bowel disease in Canada. Can J Gastroenterol Hepatol (2014) 1.19
Efficacy of the vaccination in inflammatory bowel disease. World J Gastroenterol (2013) 1.12
Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol (2013) 1.12
Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford) (2010) 1.10
Severe disease activity and cytomegalovirus colitis are predictive of a nonresponse to infliximab in patients with ulcerative colitis. Dig Dis Sci (2013) 1.03
Diagnosis and treatment of ulcerative colitis with cytomegalovirus infection: importance of controlling mucosal inflammation to prevent cytomegalovirus reactivation. Intest Res (2014) 1.03
Strategies for the care of adults hospitalized for active ulcerative colitis. Clin Gastroenterol Hepatol (2012) 1.01
CMV in the gut: a critical review of CMV detection in the immunocompetent host with colitis. Eur J Clin Microbiol Infect Dis (2014) 1.00
Usefulness of the cytomegalovirus antigenemia assay in patients with ulcerative colitis. Intest Res (2015) 0.97
Vaccines and recommendations for their use in inflammatory bowel disease. World J Gastroenterol (2013) 0.93
A guide to prepare patients with inflammatory bowel diseases for anti-TNF-α therapy. Med Sci Monit (2014) 0.91
An Australian audit of vaccination status in children and adolescents with inflammatory bowel disease. BMC Gastroenterol (2011) 0.88
Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review. World J Gastroenterol (2013) 0.87
Optimizing the use of thiopurines in inflammatory bowel disease. Ther Adv Chronic Dis (2015) 0.87
An audit of influenza vaccination status in adults with inflammatory bowel disease. Can J Gastroenterol (2012) 0.87
Inflammatory bowel diseases and human reproduction: a comprehensive evidence-based review. World J Gastroenterol (2014) 0.85
Optimizing the safety of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol (2010) 0.85
A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease. J Gastroenterol (2012) 0.85
Hospitalizations for vaccine preventable pneumonias in patients with inflammatory bowel disease: a 6-year analysis of the Nationwide Inpatient Sample. Clin Exp Gastroenterol (2013) 0.84
Atypical mycobacterial infection presenting as persistent skin lesion in a patient with ulcerative colitis. Case Rep Med (2011) 0.84
Prevention of infection caused by immunosuppressive drugs in gastroenterology. Ther Adv Chronic Dis (2013) 0.83
Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience. BMC Gastroenterol (2014) 0.82
Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents. World J Gastroenterol (2015) 0.82
Cytomegalovirus-induced Hemorrhagic Colitis in a Patient with Chronic Myeloid Leukemia (Chronic Phase) on Dasatinib as an Upfront Therapy. Clin Med Insights Case Rep (2015) 0.82
Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. World J Gastroenterol (2013) 0.82
Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis. World J Gastroenterol (2013) 0.81
Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease. World J Gastroenterol (2014) 0.81
Vaccination strategies in patients with IBD. Nat Rev Gastroenterol Hepatol (2013) 0.81
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: effects of combined therapy with immunosuppressants. J Crohns Colitis (2012) 0.81
When is an Assay of Cytomegalovirus Antigenemia Useful in Detecting Cytomegalovirus Colitis? Intest Res (2015) 0.81
Cytomegalovirus in inflammatory bowel disease: A systematic review. World J Gastroenterol (2016) 0.81
Should my patient with inflammatory bowel disease on immunosuppressive therapy be vaccinated against influenza virus? Can J Gastroenterol (2010) 0.80
Cost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn's Disease. Dig Dis Sci (2015) 0.79
Varicella zoster meningitis complicating combined anti-tumor necrosis factor and corticosteroid therapy in Crohn's disease. World J Gastroenterol (2013) 0.79
Opportunistic infections and vaccinations in IBD patients. J Crohns Colitis (2011) 0.79
Vaccination and infection prevention in inflammatory bowel disease. F1000 Med Rep (2010) 0.78
Safety and Efficacy of Granulocyte/Monocyte Apheresis in Steroid-Dependent Active Ulcerative Colitis with Insufficient Response or Intolerance to Immunosuppressants and/or Biologics [the ART Trial]: 12-week Interim Results. J Crohns Colitis (2016) 0.78
The role of tumour necrosis factor in hepatitis B infection: Jekyll and Hyde. Clin Transl Immunology (2016) 0.78
Clostridium difficile infection in patients with inflammatory bowel disease. Prz Gastroenterol (2014) 0.77
Herpes simplex induced necrotizing tonsillitis in an immunocompromised patient with ulcerative colitis. World J Clin Cases (2016) 0.77
Pneumococcal vaccination rates in VHA patients with inflammatory bowel disease. Medicine (Baltimore) (2015) 0.77
Preventing infective complications in inflammatory bowel disease. World J Gastroenterol (2014) 0.77
Biological therapy for ulcerative colitis. Gastroenterol Rep (Oxf) (2014) 0.77
Anti-tumor necrosis factor therapy and influenza: keeping it in perspective. Therap Adv Gastroenterol (2010) 0.77
Use of thiopurines in inflammatory bowel disease: Safety issues. World J Gastrointest Pharmacol Ther (2014) 0.77
Varicella zoster virus infection in patients with inflammatory bowel disease. Gastroenterol Hepatol (N Y) (2013) 0.76
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? World J Gastrointest Pharmacol Ther (2016) 0.75
Herpes simplex virus colitis complicating the course of a patient with Crohn's disease and cirrhosis: an underestimated association? Gastroenterol Hepatol (N Y) (2010) 0.75
Effects of immunosuppressants on immune response to vaccine in inflammatory bowel disease. Chin Med J (Engl) (2015) 0.75
Author's Reply. Intest Res (2015) 0.75
Evaluation of a multiplex PCR assay for detection of cytomegalovirus in stool samples from patients with ulcerative colitis. World J Gastroenterol (2015) 0.75
Influenza vaccination coverage in children with inflammatory bowel disease. Influenza Other Respir Viruses (2014) 0.75
Impact on Life Expectancy of Withdrawing Thiopurines in Patients with Crohn's Disease in Sustained Clinical Remission: A Lifetime Risk-Benefit Analysis. PLoS One (2016) 0.75
The long-term risk of continuous immunosuppression using thioguanides in inflammatory bowel disease. Ther Adv Chronic Dis (2010) 0.75
Recalcitrant plantar warts during azathioprine therapy for Crohn's disease. Ann Gastroenterol (2013) 0.75
Catheter-Related Acremonium kiliense Fungemia in a Patient with Ulcerative Colitis under Treatment with Infliximab. Case Rep Infect Dis (2011) 0.75
Varicella zoster exposure in patients with inflammatory bowel disease--recall is not enough. Am J Gastroenterol (2014) 0.75
Protracted primary cytomegalovirus infection presenting as ileoanal pouchitis in a non-immunosuppressed patient: a case report. J Med Case Rep (2014) 0.75
Effective tuberculosis and hepatitis screening prior to anti-TNF-α therapy: are we there yet? Dig Dis Sci (2014) 0.75
Working Group Guidelines on the nursing roles in caring for patients with Crohn's disease and ulcerative colitis in Poland. Prz Gastroenterol (2014) 0.75
Preventative Care in the Patient with Inflammatory Bowel Disease: What Is New? Dig Dis Sci (2016) 0.75
Immunization status in children with inflammatory bowel disease. Eur J Pediatr (2013) 0.75
Management of inflammatory bowel disease with Clostridium difficile infection. World J Gastroenterol (2017) 0.75
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 33.12
Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell (1992) 10.97
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Full-genome RNAi profiling of early embryogenesis in Caenorhabditis elegans. Nature (2005) 9.50
A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis (2000) 6.90
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis (2010) 6.75
Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J Exp Med (2001) 6.51
HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med (2000) 5.79
Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature (1996) 5.44
Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology (1998) 5.02
Dysbiosis in inflammatory bowel disease. Gut (2004) 5.01
Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut (2008) 4.41
NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut (2004) 4.39
Diabetes in institutionalised elderly people: a forgotten population? BMJ (1997) 4.30
Guidelines for the management of inflammatory bowel disease in adults. Gut (2004) 4.15
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis (2010) 3.97
Measuring physicians' performances by using simulated patients. J Med Educ (1985) 3.75
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis (2009) 3.66
Influx of extended-spectrum beta-lactamase-producing enterobacteriaceae into the hospital. Clin Infect Dis (2006) 3.64
European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut (2006) 3.59
European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut (2006) 3.57
Long-term outcome of endoscopic dilatation in patients with Crohn's disease is not affected by disease activity or medical therapy. Gut (2009) 3.50
Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. Aliment Pharmacol Ther (2013) 3.47
Capsule endoscopy in acute upper gastrointestinal hemorrhage: a prospective cohort study. Endoscopy (2012) 3.28
Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet (1996) 3.15
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut (2008) 3.14
Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science (1990) 3.04
Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol (1992) 3.00
Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut (2006) 3.00
Anaemia in inflammatory bowel disease: a population-based 10-year follow-up. Aliment Pharmacol Ther (2013) 2.90
Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients. Aliment Pharmacol Ther (2012) 2.87
Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest (1992) 2.80
A 9.0-kilobase-pair circular plasmid of Borrelia burgdorferi encodes an exported protein: evidence for expression only during infection. Infect Immun (1994) 2.74
Appendectomy protects against ulcerative colitis. Gastroenterology (1994) 2.71
Duodenal metal-transporter (DMT-1, NRAMP-2) expression in patients with hereditary haemochromatosis. Lancet (1999) 2.68
Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors. Aliment Pharmacol Ther (2012) 2.67
Great ape DNA sequences reveal a reduced diversity and an expansion in humans. Nat Genet (2001) 2.62
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology (1999) 2.62
Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut (2008) 2.60
Outcomes following acute nonvariceal upper gastrointestinal bleeding in relation to time to endoscopy: results from a nationwide study. Endoscopy (2012) 2.58
Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut (2004) 2.55
Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology (1995) 2.47
Pattern of nucleotide substitution and rate heterogeneity in the hypervariable regions I and II of human mtDNA. Genetics (1999) 2.42
Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood (2001) 2.40
In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci U S A (1993) 2.39
Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis (2001) 2.34
Genetic analyses of chromosome 12 loci in Crohn's disease. Gut (2000) 2.30
mtDNA sequence diversity in Africa. Am J Hum Genet (1996) 2.28
Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. Infect Immun (2001) 2.28
Melanesian origin of Polynesian Y chromosomes. Curr Biol (2000) 2.27
Muscle-specific overexpression of lipoprotein lipase causes a severe myopathy characterized by proliferation of mitochondria and peroxisomes in transgenic mice. J Clin Invest (1995) 2.27
Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis. Aliment Pharmacol Ther (2015) 2.25
DNA probes specific for Entamoeba histolytica possessing pathogenic and nonpathogenic zymodemes. Infect Immun (1989) 2.22
Measurement of physician performance by standardized patients. Refining techniques for undetected entry in physicians' offices. Med Care (1985) 2.21
Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut (2009) 2.20
Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Psychiatry (1985) 2.17
Prognosis of patients with nonmalignant chronic intestinal failure receiving long-term home parenteral nutrition. Gastroenterology (1995) 2.16
West Nile fever outbreak, Israel, 2000: epidemiologic aspects. Emerg Infect Dis (2001) 2.15
An in-depth study of Crohn's disease in two French families. Gastroenterology (1993) 2.15
Comparison of invasive and non-invasive tests diagnosis and monitoring of Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr (2004) 2.15
European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohns Colitis (2008) 2.14
Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. Aliment Pharmacol Ther (2010) 2.12
Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease. Int J Clin Pract (2010) 2.12
Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun (2003) 2.10
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut (2009) 2.08
A novel device to improve colon cleanliness during colonoscopy. Endoscopy (2012) 2.04
Iron, anaemia, and inflammatory bowel diseases. Gut (2004) 2.03
Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol (1998) 2.03
European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis (2008) 1.99
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther (2001) 1.94
Dysbiosis as a prerequisite for IBD. Gut (2004) 1.93